Pulmonx Total Depreciation and Amortization - Cash Flow 2019-2025 | LUNG
Pulmonx total depreciation and amortization - cash flow from 2019 to 2025. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
| Pulmonx Annual Total Depreciation and Amortization - Cash Flow (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $1 |
| 2022 | $1 |
| 2021 | $1 |
| 2020 | $1 |
| 2019 | $0 |
| 2018 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.070B | $0.084B |
| Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation is based in Redwood City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $43.991B | 53.84 |
| Tempus AI (TEM) | United States | $13.179B | 0.00 |
| Doximity (DOCS) | United States | $12.725B | 56.62 |
| Hims & Hers Health (HIMS) | United States | $9.572B | 78.43 |
| IRhythm Technologies (IRTC) | United States | $5.461B | 0.00 |
| Hinge Health (HNGE) | United States | $4.399B | 0.00 |
| Privia Health (PRVA) | United States | $2.828B | 209.45 |
| Inspire Medical Systems (INSP) | United States | $2.771B | 40.73 |
| Heartflow (HTFL) | $2.557B | 0.00 | |
| Phreesia (PHR) | United States | $1.884B | 0.00 |
| Enovis (ENOV) | United States | $1.766B | 9.34 |
| 10x Genomics (TXG) | United States | $1.744B | 0.00 |
| Omnicell (OMCL) | United States | $1.497B | 28.84 |
| Schrodinger (SDGR) | United States | $1.436B | 0.00 |
| Azenta (AZTA) | United States | $1.400B | 61.08 |
| Clover Health Investments (CLOV) | United States | $1.343B | 0.00 |
| Claritev (CTEV) | United States | $1.135B | 0.00 |
| Evolent Health (EVH) | United States | $1.134B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.679B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.652B | 0.00 |
| Veradigm (MDRX) | United States | $0.531B | 0.00 |
| Standard BioTools (LAB) | United States | $0.481B | 0.00 |
| Talkspace (TALK) | United States | $0.445B | 133.00 |
| Butterfly Network (BFLY) | United States | $0.405B | 0.00 |
| Carlsmed (CARL) | United States | $0.353B | 0.00 |
| TruBridge (TBRG) | United States | $0.300B | 52.53 |
| Outset Medical (OM) | United States | $0.247B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.239B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.234B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.213B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.195B | 0.00 |
| CapsoVision (CV) | United States | $0.175B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.168B | 0.00 |
| CareCloud (CCLD) | United States | $0.163B | 7.38 |
| American Well (AMWL) | United States | $0.111B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.109B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.077B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.072B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.060B | 0.00 |
| 111 (YI) | China | $0.056B | 0.00 |
| HeartBeam (BEAT) | United States | $0.046B | 0.00 |
| Zhongchao (ZCMD) | China | $0.025B | 0.00 |
| Precipio (PRPO) | United States | $0.025B | 0.00 |
| PROFUSA (PFSA) | United States | $0.017B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.013B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.012B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.008B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |